SCHEMBL21669239

SCHEMBL21669239

CCOC(O)C(NC(=O)OC(C)(C)C)c1ccc(OC(=O)CCS(=O)(=O)OC)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.38
PPARA Q07869 2/20 0.38
ABCB1 P08183 3/20 0.35
KMT2A Q03164 3/20 0.34
LMNA P02545 3/20 0.34
HTT P42858 3/20 0.34
HSD17B10 Q99714 3/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
GAA P10253 3/20 0.33
HPGD P15428 2/20 0.33
HIF1A Q16665 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GLA P06280 1/20 0.33
NPSR1 Q6W5P4 3/20 0.33
TP53 P04637 2/20 0.33
XBP1 P17861 2/20 0.33
MAPK1 P28482 2/20 0.33
JAK2 O60674 1/20 0.33
S1PR4 O95977 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24282828 0.91 ALDH1A1 (0.36) PPARGPPARAABCB1KMT2ALMNA
SCHEMBL21669232 0.90 PPARG (0.39) PPARGPPARAABCB1KMT2ALMNA
SCHEMBL24283195 0.89 ALDH1A1 (0.38) PPARGPPARAABCB1KMT2ALMNA
SCHEMBL24282722 0.87 KMT2A (0.39) KMT2ALMNAHTTHSD17B10ALDH1A1
SCHEMBL21669235 0.85 PPARG (0.45) PPARGPPARAABCB1LMNAHTT
SCHEMBL24282829 0.83 CA1 (0.43) KMT2AALDH1A1MAPTMMP13CTSS
SCHEMBL21669349 0.82 KMT2A (0.37) KMT2ALMNAHTTHSD17B10ALDH1A1
SCHEMBL24282880 0.82 ALDH1A1 (0.37) PPARGPPARAABCB1KMT2ALMNA
SCHEMBL24282724 0.81 MAPT (0.38) PPARGPPARAABCB1KMT2ALMNA
SCHEMBL21669305 0.78 KMT2A (0.40) KMT2ALMNAHTTHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3829568-B1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON INC (US) 2023-09-06 EP disclosed
US-20220087967-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON, INC. 2022-03-24 US disclosed
WO-2020028348-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON, INC. (US) 2020-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220087967-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS PSEN1, APP, PSEN2 PPARG 571/4885PPARA 226/4885ABCB1 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.